Biogen Inc (BIIB)

220.99
+2.77(+1.27%)
After Hours
219.91
-1.08(-0.49%)
- Real-time Data
  • Volume:
    765,846
  • Day's Range:
    218.58 - 222.17
  • 52 wk Range:
    187.16 - 351.86

BIIB Overview

Prev. Close
218.22
Day's Range
218.58-222.17
Revenue
10.82B
Open
218.58
52 wk Range
187.16-351.86
EPS
14.01
Volume
765,846
Market Cap
32.07B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,001,023
P/E Ratio
15.10
Beta
0.387
1-Year Change
-35.43%
Shares Outstanding
145,113,047
Next Earnings Date
Oct 25, 2022
What is your sentiment on Biogen?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Biogen Inc Analysis

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuySell
Technical IndicatorsSellSellStrong BuyStrong BuyStrong Sell
SummaryNeutralNeutralStrong BuyStrong BuyStrong Sell
  • no comments?
    0